Albert J. Wong, M.D.

Professional Education

Postdoctoral Advisees

Gordon Li , Ryan Nitta

Graduate & Fellowship Program Affiliations

• Cancer Biology
• Neurosurgery

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

The goal of this laboratory is to define targets for cancer therapeutics by identifying alterations in signal transduction proteins and then translate these findings into important clinical tools, including one of the first effective peptide vaccines against cancer. The major type of cancer that we study is glioblastoma multiforme, the most common and devastating of the human brain tumors, but this work has also had implications for lung, breast, ovarian and prostate cancers.

Our research direction originated when we first identified a spontaneously occurring mutant EGF receptor in glioblastoma. Known as EGFRvIII (pronounced “EGFR-v-three”), this molecule represents a deletion of exons 2 through 7 in the extracellular domain of the EGF receptor. This removes 273 amino acids and creates a novel glycine at the fusion junction. We have engaged in both very basic studies on the signal transduction pathways initiated by EGFRvIII, as well as translational work to create diagnostic tools and therapies around EGFRvIII.

Our basic science studies on understanding EGFRvIII signaling have led us to discover the Gab1 docking protein. Orignially discovered as a substrate for the EGF receptor, we and others have found that Gab1 is a substrate for numerous tyrosine kinase receptors, and in turn Gab1 recruits several proteins with SH2 domains. It is now clear that it is a vital link for multiple growth factor and cytokine pathways and has a role in diverse phenotypes such as cell survival, the cellular response to stress, and the cellular entry of parasites.

As another result of our efforts on signaling pathways, we have discovered that glioblastoma tumors preferentially utilize the JNK pathway, unlike many other tumors that use the ERK pathway. More specifically, only one of the 12 known JNK isoforms is highly expressed, JNK2a2. Co-incidentally, we have uncovered that this isoform is constitutively active and that it has a specific activation...

Clinical Trials

• PI EGFRvIII Peptide Vaccination after Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas Not yet recruiting

Publications

• The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas. Li G, Mitra S, Wong AJ. Neurosurg Clin N Am. 2010; 21 (1): 87-93
• EGF receptor variant III as a target antigen for tumor immunotherapy. Li G, Wong AJ. Expert Rev Vaccines. 2008; 7 (7): 977-85
• Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation. Nitta RT, Chu AH, Wong AJ. J Biol Chem. 2008; 283 (50): 34935-45
• The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation. Laramée M, Chabot C, Cloutier M, Stenne R, Holgado-Madruga M, Wong AJ, Royal I. J Biol Chem. 2007; 282 (11): 7758-69
• Beta1 integrins modulate cell adhesion by regulating insulin-like growth factor-II levels in the microenvironment. Goel HL, Moro L, King M, Teider N, Centrella M, McCarthy TL, Holgado-Madruga M, Wong AJ, Marra E, Languino LR. Cancer Res. 2006; 66 (1): 331-42